Additionally, Olsen, who is the company’s current chief operating officer, will continue to serve in that capacity for both divisions while the board of directors engages in a search for Hernandez’ successor.
IBI is engaged in developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets.